Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Congress Reviews Ranbaxy Approvals

July 28, 2008 | A version of this story appeared in Volume 86, Issue 30

As part of an ongoing investigation into FDA's ability to ensure that food and drugs sold in the U.S. are safe, House Committee on Energy & Commerce Chairman John D. Dingell (D-Mich.) and committee member Rep. Bart Stupak (D-Mich.) sent a letter to FDA Commissioner Andrew C. von Eschenbach on July 22 questioning whether the agency knowingly allowed India's generic drugmaker Ranbaxy to sell substandard drugs in the U.S. (C&EN, July 21, page 10). The letter is in response to a motion, filed by the Department of Justice on July 3 in U.S. District Court for the District of Maryland, that indicates FDA knew about Ranbaxy's alleged "pattern of systemic fraudulent conduct" for at least 18 months. The committee intends to review the premarket approval inspections and "for cause" inspections, which are triggered by suspicious activity, for all Ranbaxy drugs sold in the U.S. to determine whether FDA can justify leaving the products on the market.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.